[{"address1": "43 Thorndike Street", "city": "Cambridge", "state": "MA", "zip": "02141", "country": "United States", "phone": "617 682 0917", "website": "https://amylyx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 123, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joshua B. Cohen", "age": 32, "title": "Co-Founder, Co-CEO & Director", "yearBorn": 1992, "fiscalYear": 2024, "totalPay": 1225305, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Justin B. Klee", "age": 33, "title": "Co-Founder, Co-CEO & Director", "yearBorn": 1991, "fiscalYear": 2024, "totalPay": 1225305, "exercisedValue": 0, "unexercisedValue": 80245}, {"maxAge": 1, "name": "Mr. James M. Frates M.B.A.", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 806277, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gina M. Mazzariello J.D.", "age": 53, "title": "Chief Legal Officer & General Counsel", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 715494, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tom  Holmes", "title": "Chief Technical Operations Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lindsey  Allen", "title": "Head of Investor Relations & Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Linda A. Arsenault", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tammy  Sarnelli", "title": "Global Head of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Machelle  Manuel Ph.D.", "title": "VP & Head of Global Medical Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jamie  Timmons", "title": "Head of Global Medical Strategy & Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 14.0, "open": 14.2, "dayLow": 12.7, "dayHigh": 14.2, "regularMarketPreviousClose": 14.0, "regularMarketOpen": 14.2, "regularMarketDayLow": 12.7, "regularMarketDayHigh": 14.2, "payoutRatio": 0.0, "beta": -0.328, "forwardPE": -7.145946, "volume": 780822, "regularMarketVolume": 780822, "averageVolume": 1626895, "averageVolume10days": 2022270, "averageDailyVolume10Day": 2022270, "bid": 10.08, "ask": 16.33, "bidSize": 2, "askSize": 2, "marketCap": 1500795520, "fiftyTwoWeekLow": 2.6, "fiftyTwoWeekHigh": 15.145, "allTimeHigh": 41.93, "allTimeLow": 1.575, "priceToSalesTrailing12Months": -6027.291, "fiftyDayAverage": 10.0679, "twoHundredDayAverage": 5.92015, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1073480064, "profitMargins": 0.0, "floatShares": 58615995, "sharesOutstanding": 106667432, "sharesShort": 8774952, "sharesShortPriorMonth": 7433417, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.08229999, "heldPercentInsiders": 0.079450004, "heldPercentInstitutions": 0.78999, "shortRatio": 4.68, "shortPercentOfFloat": 0.0892, "impliedSharesOutstanding": 113524624, "bookValue": 1.883, "priceToBook": 7.020712, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -187600000, "trailingEps": -2.4, "forwardEps": -1.85, "enterpriseToRevenue": -4311.165, "enterpriseToEbitda": -5.469, "52WeekChange": 3.7619047, "SandP52WeekChange": 0.17741585, "quoteType": "EQUITY", "currentPrice": 13.22, "targetHighPrice": 25.0, "targetLowPrice": 10.0, "targetMeanPrice": 14.875, "targetMedianPrice": 13.0, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 180826000, "totalCashPerShare": 2.028, "ebitda": -196296992, "totalDebt": 5962000, "quickRatio": 8.45, "currentRatio": 8.723, "totalRevenue": -249000, "debtToEquity": 3.551, "revenuePerShare": -0.003, "returnOnAssets": -0.46742, "returnOnEquity": -0.87421, "grossProfits": -94523000, "freeCashflow": -167043376, "operatingCashflow": -165650000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 791.0643, "financialCurrency": "USD", "symbol": "AMLX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Amylyx Pharmaceuticals, Inc.", "longName": "Amylyx Pharmaceuticals, Inc.", "firstTradeDateMilliseconds": 1641565800000, "hasPrePostMarketData": true, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1626895, "fiftyTwoWeekLowChange": 10.620001, "fiftyTwoWeekLowChangePercent": 4.0846157, "fiftyTwoWeekRange": "2.6 - 15.145", "fiftyTwoWeekHighChange": -1.9250002, "fiftyTwoWeekHighChangePercent": -0.12710467, "fiftyTwoWeekChangePercent": 376.19046, "marketState": "REGULAR", "corporateActions": [], "regularMarketTime": 1759419385, "exchange": "NMS", "messageBoardId": "finmb_317169670", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -5.559513, "regularMarketPrice": 13.22, "regularMarketChange": -0.77999973, "regularMarketDayRange": "12.7 - 14.2", "earningsTimestamp": 1754539200, "earningsTimestampStart": 1762432200, "earningsTimestampEnd": 1762432200, "earningsCallTimestampStart": 1754568000, "earningsCallTimestampEnd": 1754568000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.4, "epsForward": -1.85, "epsCurrentYear": -1.72965, "priceEpsCurrentYear": -7.6431646, "fiftyDayAverageChange": 3.1521006, "fiftyDayAverageChangePercent": 0.31308421, "twoHundredDayAverageChange": 7.2998505, "twoHundredDayAverageChangePercent": 1.2330517, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-01-07", "cryptoTradeable": false, "displayName": "Amylyx Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-10-02"}]